Concomitant KRAS and PIK3CA mutations among the tumor, plasma, and peritoneal fluid in EC have been reported using targeted sequencing of gDNA derived from tissues and quantitative polymerase chain reaction (PCR) assay for ctDNA derived from the plasma and peritoneal fluid [12]. The gene discussed is PIK3CA; the disease is neoplasm.